Misty Shields, Assistant Professor at Indiana University School of Medicine, Indiana University Health, shared on LinkedIn:
“Dr. Julia Rotow presents the Destiny-Lung-04 data of trastuzumab deruxtecan vs pembro+chemo in 1L HER2 NSCLC at IASLC FOUNDATION WCLC26.
T-DXd improved PFS and ORR, yet OS benefit is limited with this regimen, likely confounded by access to 2L HER2-directed therapies.
AEs notable with ILD 20.8% (>4% G3+).
Difficult to know how T-DXd will fit in the sequencing of an evolving HER2 landscape with available TKIs zongertinib and sevabertinib.”
Other articles featuring Misty Shields on OncoDaily.
